AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 222
(I-22)

Introduced by: Washington

Subject: Allocate Opioid Funds to Train More Addiction Treatment Physicians

Referred to: Reference Committee B

Whereas, There are not enough medical physicians in the U.S. actively prescribing medications for opioid use disorder, especially in rural areas; and

Whereas, $26 billion in opioid settlement funds are available nationally from the “Big Three” drug distributors AmerisourceBergen, Cardinal Health, and McKesson, and opioid manufacturer Johnson & Johnson; therefore be it

RESOLVED, That our American Medical Association amend Policy H-95.918, “Holding the Pharmaceutical Industry Accountable for Opioid-Related Costs,” by addition to read as follows:

Our AMA will advocate that any monies paid to the states, received as a result of a settlement or judgment, or other financial arrangement or agreement as a result of litigation against pharmaceutical manufacturers, distributors, or other entities alleged to have engaged in unethical and deceptive misbranding, marketing, and advocacy of opioids, be used exclusively for research, education, prevention, and treatment of overdose, opioid use disorder, and pain, as well as expanding physician training opportunities to provide clinical experience in the treatment of opioid use disorders.

(Modify Current HOD Policy)

Fiscal Note: Not yet determined

Received: 10/10/22

REFERENCES:


RELEVANT AMA POLICY

Holding the Pharmaceutical Industry Accountable for Opioid-Related Costs H-95.918
Our AMA will advocate that any monies paid to the states, received as a result of a settlement or judgment, or other financial arrangement or agreement as a result of litigation against pharmaceutical manufacturers, distributors, or other entities alleged to have engaged in unethical and deceptive misbranding, marketing, and advocacy of opioids, be used exclusively for research, education, prevention, and treatment of overdose, opioid use disorder, and pain.
Citation: Res. 204, A-19;

Improving Residency Training in the Treatment of Opioid Dependence H-310.906
Our AMA: (1) encourages the expansion of residency and fellowship training opportunities to provide clinical experience in the treatment of opioid use disorders, under the supervision of an appropriately trained physician; and (2) supports additional funding to overcome the financial barriers that exist for trainees seeking clinical experience in the treatment of opioid use disorders.
Citation: Res. 301, I-16